19.09.2016 13:07:07

Lannett Says FDA Completes CGMP Inspections Of Three Facilities - Quick Facts

(RTTNews) - Lannett Company, Inc. (LCI), a developer of generic pharmaceutical products, announced Monday that the U.S. Food and Drug Administration or FDA recently completed a cGMP inspection of the company's manufacturing facility in Philadelphia. The FDA also completed inspections of two facilities located in Armenia: Darmantest Laboratory, the company's pharmacokinetic subsidiary, and Firmplace, a stability laboratory with which the company has a strategic relationship.

The inspections concluded with two minor 483 observations at the company's facility in Philadelphia and zero observations at the laboratories in Armenia.

Arthur Bedrosian, chief executive officer of Lannett, said, "At a time of particularly rigorous scrutiny by FDA, we achieved a trifecta of successful inspections at our facilities. Compliance with Current Good Manufacturing Practices (cGMP) provides confidence to our customers and, ultimately patients, that our products are manufactured under strict adherence to the highest level of quality standards."

Bedrosian added that passing inspection at its overseas stability and bio-study laboratories is an important milestone. It paves the way to ramp up product development efforts at these locations and reduce certain R&D costs going forward.

Nachrichten zu Lannett Co Inc Registered Shs (Old)mehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Lannett Co Inc Registered Shs (Old)mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!